Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Benjamin L. Palleiko, Chief Executive Officer of KalVista Pharmaceuticals (NASDAQ:KALV), sold 32,979 shares of common stock on July 9, 2025, at a price of $15.6925, for a total transaction value of $517,522. The sale comes as the stock trades near its 52-week high of $16.32, with InvestingPro data showing an impressive 97.58% return over the past six months.
The sale was to cover tax withholding obligations related to the vesting and settlement of performance stock units (PSUs). On July 8, 2025, Palleiko also acquired 87,500 shares of common stock as a result of the vesting of PSUs granted on January 11, 2023, upon achievement of performance metrics. Each PSU represents the right to receive one share of KalVista’s common stock. The company, currently valued at $795 million, maintains strong liquidity with more cash than debt on its balance sheet.
Following these transactions, Palleiko directly owns 369,595 shares of KalVista Pharmaceuticals. For deeper insights into KALV’s valuation and 14 additional exclusive ProTips, visit InvestingPro.
In other recent news, Kalvista Pharmaceuticals Inc has made significant strides with the FDA approval of Ekterly, the first oral on-demand treatment for hereditary angioedema (HAE) attacks. This approval has led several analyst firms to adjust their price targets for the company. Leerink Partners reiterated an Outperform rating and increased its price target to $20.00, while BofA Securities raised its target to $37.00, citing Ekterly’s unique position in the market. JMP Securities also increased its price target to $27.00, projecting peak sales of $740 million for Ekterly. The drug, priced at $16,720 per dose, is anticipated to capture significant market share due to its convenience and efficacy.
Kalvista has prepared for a robust launch with patient support programs like KalVista Cares, and has secured commercialization agreements for international markets, including Germany, Japan, and the United Kingdom (TADAWUL:4280). Stifel has maintained a Buy rating with a $39.00 price target, noting the favorable label and potential for rapid market adoption. Analysts are closely monitoring the initial launch metrics to assess the drug’s market dynamics and uptake. These developments mark a pivotal moment for Kalvista as it positions Ekterly in the competitive HAE treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.